CA19-9升高非小细胞肺癌患者的病理特征及预后  

Relationship between CA19-9 elevation and pathological features of non-small cell lung cancer(NSCLC)and prognosis

作　　者：李星辰 房芳 高梦丽 刘华群 王亚囡 宋文广 Li Xingchen;Fang Fang;Gao Mengli;Liu Huaqun;Wang Yanan;Song Wenguang(Department of Oncology,Affiliated Tangshan Gongren Hospital of North China University of Technology,Tangshan Hebei 063003)

机构地区：[1]华北理工大学附属唐山市工人医院肿瘤内一科,河北唐山063003

出　　处：《山西中医药大学学报》2021年第3期198-201,共4页Journal of Shanxi University of Chinese Medicine

基　　金：河北省卫健委医学科研课题(20201496)。

摘　　要：目的:分析CA19-9升高的非小细胞肺癌(NSCLC)患者的临床特征,探讨CA19-9升高对NSCLC患者预后的价值。方法:本研究回顾性分析了189例NSCLC患者的临床资料及肿瘤标记物情况,将患者分为CA19-9升高组和CA19-9正常组2个队列,比较两组在病理及基因类型、分期、转移特点和生存预后等方面的差异。结果:在189例患者中CA19-9升高比例为29.1%(55/189),升高组中87.27%为腺癌;在具备基因检测结果的病例中,血清CA19-9水平与EGFR和KRAS基因状态未显示相关性;CA19-9升高的Ⅳ期患者中肝转移发生率显著高于正常组肝转移的发生率(33.33%vs 15.22%)(P<0.05),其他脏器转移发生率比较差异无统计学意义;正常组平均生存期显著高于CA19-9升高组的患者(P=0.001)。结论:CA19-9升高主要见于肺腺癌患者,未发现与基因分型有相关性,同时,CA19-9升高预示着患者的分期更晚、病变更广泛、预后更差。Objective:To investigate the pathological features of non-small cell lung cancer(NSCLC)patients with CA19-9 elevation and prognostic values of CA19-9 elevation on NSCLC patients.Methods:This study retrospectively analyzed the clinical data and tumor markers of 189 NSCLC patients,who were divided into the CA19-9 elevation group and the normal CA19-9 group,by comparing the differences in the pathological type,gene type,stage,metastasis characteristics and survival prognosis.Results:Among the 189 patients,the total ratio of CA19-9 elevation was 29.1%(55/89),and 87.27%of patients in CA19-9 elevation group were adenocarcinoma.There was no significant correlation between serum CA19-9 level and EGFR,KRAS gene status.In patients of clinical stage IV in CA19-9 elevation group,the frequency rate of liver metastasis was significantly higher than that in patients of clinical stage IV in normal CA19-9 group(33.33%vs 15.22%)(P<0.05),but there was no statistical significance in the frequency rate of other organ metastases.The average survival time in normal CA19-9 group was significantly higher than that in CA19-9 elevation group(P=0.001).Conclusions:CA19-9 elevation is mainly seen in patients with lung adenocarcinoma,but it does not do matter with the type of gene.Meanwhile,the CA19-9 elevation may indicates a later staging,broader disease changes and worse prognosis.

关 键 词：非小细胞肺癌 CA19-9 EGFR KRAS 肝转移 预后 

分 类 号：R734.2[医药卫生—肿瘤]